Archive

ASH 2015: Good news for patients from ASH! Erik Low (Chief Executive Myeloma UK), Professor Antonio Palumbo (University of Torino, Italy), Professor Paul Richardson (Harvard Medical School, Boston, USA) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA) discuss the things they will take home to their myeloma patients folloing ASH 2015

ASH 2015: Video Interview by Esther Drain. CDF changes affecting myeloma patients. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Erik Low (Chief Executive Myeloma UK) discuss recent changes in the CDF and how they affect myeloma patients.

ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.

ASH 2015: Video Interview by Esther Drain. Myeloma XI initial response data at ASH. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) discusses the initial response data from Myeloma XI and whether early intensive therapy is the way forward in managing myeloma, with comment also from Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA).

ASH 2015: Ernest Beutler Lecture Prize: Award-winners trace history of proteasome and its starring role in MM treatment: Interview with Alfred Goldberg, PhD, Professor of Cell Biology at Harvard Medical School, and Paul Richardson, MD, Professor of Medicine at the Dana-Farber Cancer Center

by Thomas R. Collins: Standing at the center of a decade and a half of stunning advancements in the treatment of multiple myeloma is the ubiquitin proteasome pathway… read more.

ASH 2015: Myeloma X (intensive) trial update: Professor Gordon Cook (Leeds Teaching Hospitals, UK) gives an update on Myeloma X and discusses the role of transplant in myeloma in the age of novel agents

ASH 2015: Professor Antonio Palumbo (University of Torino, Italy), Dr Shaji Kumar (Mayo Clinic, Rochester, USA), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) give their highlights.

Ozone raises risk of acute respiratory disease syndrome in critically ill patients

by Bruce Sylvester: Ozone exposure appears to be associated with acute respiratory disease syndrome (ARDS) in some critically ill patients, according to research published on Dec. 17, 2015… read more.

ASH 2015 Video Interview by Esther Drain: Association of gene expression profiling, Interim PET, EBV status and PD-L1 expression in cHL. An interview with Dr Cathy Burton (Clinical Haematologist, Leeds Teaching Hospitals, UK)

ASH 2015 Video Interview by Esther Drain: Is oral as effective as IV or sub cutaneous administration? Professor Philippe Moreau (University Hospital, Nantes, France), Professor Gordon Cook (Leeds Teaching Hospitals, UK) and Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discuss whether the trend towards new oral agents for myeloma will mean a choice between efficacy and convenience… or in fact whether both can be achieved

ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)

Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.

ASH 2015 Video Interview by Esther Drain: Erik Low (Chief Executive Myeloma UK), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) discuss how and when we might expect our patients to have access to the therapies now available to US myeloma patients